Abstract CT198: Immunomodulatory effects of the ATR inhibitor ceralasertib in a window of opportunity biomarker trial in patients with head and neck squamous cell carcinoma
Gemma N. Jones(AstraZeneca (United Kingdom)), Umamaheswar Duvvuri(City University of New York), Richard Bystry(AstraZeneca (United Kingdom)), Jaime Rodriguez‐Canales(National Cancer Institute), Elizabeth A. Harrington(AstraZeneca (United Kingdom)), Pei‐Jen Lou(National Taiwan University), Bienvenu Loembé(AstraZeneca (Netherlands)), Sophie E. Willis(AstraZeneca (United Kingdom)), Natalia Lukashchuk(AstraZeneca (United Kingdom)), Elhan Sanai(AstraZeneca (United Kingdom)), Sonia Iyer(Whitehead Institute for Biomedical Research), Marta Milo(AstraZeneca (Brazil)), Shaan Gill(AstraZeneca (United Kingdom)), Paola Marco‐Casanova(AstraZeneca (United Kingdom)), Alan Lau(AstraZeneca (United Kingdom)), M Alexandrová(AstraZeneca (United Kingdom)), Michael Surace(AstraZeneca (Netherlands)), Andreas Dannhorn(AstraZeneca (United Kingdom)), Melonie A. Nance(Anna Needs Neuroblastoma Answers), Emma Dean(AstraZeneca (United Kingdom)), Nathan Standifer(Serimmune (United States)), Carlos Gomez‐Roca(Université Fédérale de Toulouse Midi-Pyrénées)
Cited by 3
Related Papers
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431